Information Provided By:
Fly News Breaks for January 27, 2020
AZN, PHAS
Jan 27, 2020 | 12:20 EDT
William Blair analyst Matt Phipps maintained an Outperform rating on PhaseBio (PHAS) after AstraZeneca (AZN) announced Phase III THALES study results for Brilinta, which noted an increased bleeding rate was observed in the Brilinta plus aspirin arm compared with the aspirin alone arm. The analyst noted that this adds a potential new addressable market for PhaseBio's PB2452, a reversal agent for the antiplatelet activity of Brilinta, assuming approval of Brilinta.
News For PHAS;AZN From the Last 2 Days
AZN
AZN
AZN
Apr 25, 2024 | 05:52 EDT
Consensus $4.56. Backs FY24 revenue view up low double-digit to low teens percentage, consensus $50.95B. Sees FY24 core tax rate 18%-22%.
AZN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.